Glucocorticoid Resistance in the Upper Respiratory Airways by Valera, Fabiana C.P. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 20 
 
 
 
 
© 2012 Valera et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Glucocorticoid Resistance in  
the Upper Respiratory Airways 
Fabiana C.P. Valera, Edwin Tamashiro and Wilma T. Anselmo-Lima 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/53105 
1. Introduction 
The nasal mucosa is known to be the first important barrier against inhalants of the 
respiratory tract. In contrast to initial opinion, this tissue actively interacts with external 
factors, producing a wide combination of mediators in response to aggressor agents [1]. In 
this respect, it is easy to understand why the nasal mucosa is predisposed to the 
development of several chronic inflammatory diseases, with rhinitis and rhinosinusitis 
being the most common disorders.  
According to the ARIA guideline [2], the prevalence of allergic rhinitis has increased in the 
last years and has been found to be around 25% in Europe [3]. The prevalence of symptoms 
related to chronic rhinosinusitis is about 15% in the USA, being the second most prevalent 
chronic condition in the American population [4]. 
The most common and studied cause of chronic rhinitis is allergic rhinitis (AR) [2]. AR is a 
nasal inflammatory disease in which the allergen induces IgE-mediated inflammation. The 
mediators released by the nasal mucosa will finally lead to intense inflammatory cell 
recruitment (predominantly eosinophils) [5], epithelial metaplasia (more pronounced in 
perennial AR) [6], and noticeable stromal edema, especially due to the action of matrix 
metalloproteinases [7]. This response to allergens will finally induce the classical symptoms 
of AR, such as sneezing, itching, nasal discharge and nasal obstruction. These symptoms 
considerably impair the quality of life, affecting sleep quality, concentration during 
work/school, and other daily activities [2]. 
Chronic rhinosinusitis can be subdivided into two forms: chronic rhinosinusitis without 
nasal polyps (CRSsNP) and with nasal polyps (CRSwNP). These two entities are almost 
clinically identical, and it is very difficult to differentiate them based only on nasal 
symptoms [8]. Both forms present variable degrees of facial pain, decreased sense of smell, 
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nasal discharge and nasal congestion. Clinically, the differentiation of these two entities is 
made by the detection of nasal polyps by nasal endoscopy. However, the major differences 
between CRSsNP and CRSwNP concern histology and molecular biomarkers [9]. CRSsNP is 
characterized by neutrophil recruitment, light edema, increased remodelling [9] and a Th1-
subset profile. In contrast, CRSwNP is characterized by an eosinophil recruitment, intense 
oedema, loose connective tissue and a Th1/Th2 mixed –subset profile, but with remarkable 
Th2 polarization [8-10].  
2. Cellular and molecular knowledge in nasal inflammatory diseases 
2.1. Allergic Rhinitis 
The development of signs and symptoms that characterize allergic rhinitis (AR) depends on 
three events: sensitization to an allergen, degranulation of inflammatory mediators after re-
exposure to the allergen (early phase) and infiltration of inflammatory cells into the tissue 
(late phase). 
The respiratory nasal mucosa is continuously exposed to several particles that are deposited 
on the mucous blanket that covers the respiratory epithelium. These antigens are processed 
by antigen-presenting cells (APCs) such as Langerhans cells, that are later presented to a 
naïve lymphocyte through a major histocompatibility complex (MHC) class II molecule [11]. 
For reasons not completely elucidated, naïve lymphocytes (Th0) differentiate into Th2 
lymphocytes and produce and release a pool of cytokines characteristic of the Th2 response 
pattern (IL-3, IL-4, IL-5, IL-9, IL-10, IL-13, GM-CSF). Moreover, the differentiated Th2 
lymphocytes stimulate the production of specific IgE by plasmocytes through IL-3 and IL-4, 
and inhibit the differentiation of Th0 lymphocytes into Th1, as well as its messenger 
molecules. This selective environment polarized to a Th2 response is typically seen in 
allergic mechanisms, such as AR, asthma and atopic dermatitis, and in helminthic infections. 
B cells that recognize the processed antigen and receive appropriate contact signals (CD40-
CD40) and molecular stimuli (IL-4, IL-6, IL-10, IL-13) start to produce specific IgE. In the 
presence of continuous antigen stimulation, B-cells switch from the production of a low-
affinity IgE molecule to the production of a high-affinity one [11]. 
Once high-affinity IgE circulates in the plasma and interstitial fluid, it binds to the Fc 
receptors. These receptors are present on the surface of mast cells and basophils, and are 
responsible for activating these cells when exposed to the binomial antibody-pathogen. 
After mast cells leave the post-capillary venules, they are able to reside in the stroma of the 
nasal submucosa and intraepithelially, probably by the production of several proteases. 
Resident mast cells are also able to produce some cytokines related to Th2 polarization (IL-4, 
IL-5), which in turn can cause an increased cell proliferation and survival time. In allergic 
mucosa, for instance, mast cells proliferate at a higher rate compared to a non-allergic 
environment, probably by the effect of Th2 cytokines [12, 13]. 
In a second phase, after sensitization and priming of resident mast cells with IgE, the 
respiratory mucosa becomes susceptible to a new exposure. When the specific inspired 
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allergen binds to the complex IgE-mediator cell, massive degranulation of allergic molecules 
(either already existent and newly synthetized) are released in the extracellular 
compartment. Histamine is the main molecule released and involved in the early phase of 
symptoms of AR, but other mediators such as leukotriene, bradykinin, prostaglandins, 
platelet activating factor, and even some proteases (tryptase and chymase) and cytokines 
(TNF-α, IL-4, IL-5) also have a role in the development of allergic symptoms [14]. These 
mediators lead to the classical early symptoms of sneezing, itching, rhinorrhea, and nasal 
congestion that occur within a few minutes after allergen exposure (5-30 minutes). These 
symptoms are the consequence of direct actions of these mediators on different resident cells 
[15]. Glands are stimulated by leukotrienes and chymases to produce and release mucous 
secretions. Endothelial cells of post-capillary venules are affected by histamine, bradykinin, 
platelet activating factor and leukotrienes, inducing vasodilatation, increased vascular 
permeability and cell adhesion. Peripheral sensory endings are stimulated by histamine type 
1 receptors on nociceptive type C fibers that generate an uncomfortable sensation of pain 
and pressure, sneezing and itching [16]. As the nasal mucosa is constantly assaulted by 
physical and chemical agents, the disruption of some areas facilitates the exposure of 
allergens to allergic mediator cells. 
After the IgE-mediated inflammatory burst triggered by the allergen, some individuals 
present total clearance of mediators and have complete resolution of symptoms after some 
minutes. However, a significant percentage (60-70%) of the allergic population develops the 
late AR response due to the recruitment of inflammatory cells into the nasal mucosa. The 
increased vascular permeability added to the expression of adhesion molecules (ICAM-1) 
and production of chemokines, recruits a variety of inflammatory cells that include 
eosinophils and basophils and, to a lesser extent, neutrophils and other leukocytes. 
The late phase typically occurs 4-6 hours after the allergen contact and is clinically 
represented by the nasal obstruction and congestion caused by mucosal edema. Toxic 
products of eosinophils, such as eosinophil cationic protein (ECP), major basic protein 
(MBP), eosinophil-derived neurotoxin and eosinophil peroxidase, are evident during the 
late phase and are proportional to the eosinophil recruitment. These highly charged proteins 
bind to proteoglycans and hyaluronic acid and cause cell damage and epithelial detachment. 
Other important inflammatory mediators involved in the late phase are leukotrienes, 
histamine, and cytokines of the Th2 response (IL-5, IL-6, GM-CSF) [17, 18]. Interestingly, the 
recruited eosinophils are able to promote an auto-positive feedback to prolong their survival 
and recruitment into the tissue, which ultimately leads to an independent eosinophilic 
inflammation (Figure 1). IL-3, IL-5, and GM-CSF are Th2 cytokines that reduce apoptosis 
and prolong eosinophil cell survival. Besides, IL-5, eotaxin and RANTES produced by 
eosinophils and other infiltrated cells recruit even more eosinophils to the inflammatory site, 
explaining the reason why a chronic allergic inflammation can be seen even when the 
allergen is not present [19].  
Lymphocytes are another group of cells that may play an important role in the late phase of 
AR. Memory T cells, T-cytotoxic and B cells have been demonstrated to be increased in AR 
compared to other forms of non-allergic rhinitis and to controls [20].  
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Figure legend: Ag: antigen; APC: antigen presenting cell; TSLP: thymic stromal lymphopoietin; TLR: toll-like receptor; 
IL: interleukin; TNF: tumor necrosis factor; TF: transcriptor factor; Ig: immunoglobulin; GM-CSF: granulocyte 
macrophage colony-stimulating factor; LT: leukotriene; PG: prostaglandin; ECP: eosinophil cationic protein; MBP: 
major basic protein; PAF: platelet activating factor 
Figure 1. Cellular and molecular events involved in the early and late phase response of AR. Initially, 
the antigen invades the cell, and either binds to the APC (antigen presenting cell) or activates innate 
immune response through TSLP or TLR-4. These mechanisms together will activate adaptative immune 
response, and T cells are triggered to Th2 response, producing cytokines as IL-4, IL-5 and IL-13. These 
cytokines will induce epithelial cells to produce rhinorrhea and will recruit inflammatory cells (as 
eosinophils) to nasal mucosa. Eosinophils will produce several cytokines that will lead to nasal 
obstruction. B cells are activated and produce IgE, which, among the antigen itself, will induce the mast 
cell to secrete histamine, leukotrienes and prostaglandins, among others, finally leading to the 
symptoms of sneezing and itching. 
Resident cells may also participate in the late phase and development of chronic allergic 
inflammation. Nasal epithelial cells express an increased number of pro-inflammatory 
cytokines such as IL-1α, IL-1β, IL-6, IL-8 and GM-CSF in allergic patients [21, 22]. Also, 
epithelial cells are the main source of thymic stromal lymphopoietin (TSLP) on the nasal 
mucosa, an important cytokine that drives T cells to produce Th2 cytokines [23] and is 
increased in AR patients compared to controls [24]. Submucosal glands located in the lamina 
propria are substantially increased in allergic patients (25%) compared to non-allergic 
individuals (15%), consistent with the chronic state of increased production of nasal 
secretions [25] 
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In summary, the cellular and molecular mechanisms of AR involve B cell production of IgE 
and mast cell/basophil priming, activation of resident cells, recruitment of inflammatory 
cells and, in some circumstances, induction of a persistent inflammatory reaction 
maintained by a positive feedback.  
2.2. Chronic Rhinosinusitis (CRS) 
Chronic Rhinosinusitis (CRS) is clinically defined as the persistence of signs and symptoms  
such as nasal obstruction, nasal congestion, rhinorrhea, facial pain, cough, and loss of smell 
for more than 12 weeks, confirmed by nasal endoscopy or computed tomography. It is 
related to an inflammatory process of the mucoperiosteal pavement of the sinonasal cavity, 
whose etiology can be clearly defined in a few subgroups of patients, involving mechanical 
obstruction, immunodeficiency, cystic fibrosis, and ciliary dyskinesia. However, in the 
majority of cases, the etiology of CRS cannot be determined. Some investigators have raised 
different hypotheses for the pathogenesis of CRS such as disruption of the epithelial barrier, 
allergy, exposure to pollutants, maintenance of mucosal inflammation due to underlying 
osteitis, persistence of bacterial biofilms, and overreaction to staphylococcal superantigens or 
fungus. It is interesting to note that individually these theories do not apply to all patients but 
may explain the pathogenicity in some cases. Despite the unrevealed etiopathogenesis, recent 
advances have been made in the elucidation of the cellular and molecular events involved in 
different situations of CRS. Based on molecular phenotyping studies, the classification of CRS 
into two different clinical subsets has been currently accepted: CRS without nasal polyps (CRS 
sine NP, CRSsNP) and CRS with nasal polyps (CRSwNP) [8, 26]. Clinically, the symptoms of 
both types are very similar to each other, with slight differences in the severity of nasal 
congestion, nasal obstruction, rhinorrhea, postnasal drip, change in the sense of smell, cough, 
and facial pain. In terms of physical examination, they differ by the presence or absence of 
nasal polyps extruding from the middle meatus of the nasal cavity. This simple difference 
noted by nasal endoscopy involves profound differences in cellular and molecular aspects that 
might be related to the prognosis and treatment of these two subsets of CRS. 
Histologically, both forms of CRS are marked by niches of denuded respiratory epithelium 
with associated metaplasia, basal membrane thickening, and goblet cell hyperplasia. The 
histology of submucosal stroma demonstrates clear differences between CRSwNP and 
CRSsNP. In CRSwNP, the submucosal stroma usually is found with robust edema and low 
cellularity, in contrast to CRSsNP that characteristically involves more pronounced fibrosis 
and less edema [9]. 
In CRSwNP, eosinophilic infiltration is the hallmark of chronic inflammation. For reasons 
not fully elucidated, there is an increased expression of pro-inflammatory cytokines (IL-1β) 
mediated by transcription factors. These cytokines mediate the recruitment of inflammatory 
cells (eosinophils, lymphocytes, neutrophils, mast cells) through the up-regulation and 
expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines (IL-8, eotaxin, and 
RANTES). In CRSwNP, the striking influx of inflammatory cells, especially eosinophils, into 
the stroma, leads to a positive feedback recruitment similar to allergic rhinitis [27]. In the 
 Glucocorticoids – New Recognition of Our Familiar Friend 528 
Caucasian CRS population, nasal polyps are remarkably characterized by a mixed 
expression of Th1 (INF-γ, IL-8) and Th2 cytokines, with an imbalance favoring the Th2 
response. Th2 cytokines (IL-3, IL-5, GM-CSF) are produced by eosinophils and Th2 cells and 
increase eosinophil recruitment and survival, creating an autonomous inflammatory cycle 
even after the removal of the initial trigger. (Figure 2) 
 
Figure legend: NF-κB: nuclear factor- κB; STAT: signal transducers and activators of tranascription; NFAT: nuclear 
factor of activated T-cells; AP: activator protein; IL: interleukin; FGF: fibroblast growth factor; TGF: transforming 
growth factor; Treg: regulatory T cell;  GM-CSF: granulocyte-macrophage colony-stimulating factor; ECP: eosinophil 
cationic protein; LT: leukotriene; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase; 
RANTES: regulated on activation, normal T cell expressed and secreted; ICAM: intercellular adhesion molecule; 
VCAM: vascular cell adhesion molecule; Th: T helper cell 
Figure 2. Cellular and molecular events involved in the pathogenesis of CRSwNP. 
Despite the similarities to allergic rhinitis and contrary to some speculations raised in the 
first studies, the eosinophilic infiltration and activation found in CRSwNP is not dependent 
on allergic mechanisms mediated by IgE [28, 29]. In the Chinese population, however, 
CRSwNP has been characterized by a different Th pattern of inflammation. A mixed 
Th1/Th17 has been found instead of the Th1/Th2 pattern, with a significantly lower GATA-3 
(Th2 specific) expression and higher IL-17 levels in the polyp tissue. The Th17 response 
drives a more neutrophilic infiltration rather than an eosinophilic recruitment [30]. 
Another important feature of CRSwNP is the impaired regulatory modulation promoted by 
Treg cells, which balances the T helper cell response. Low levels of Treg cell biomarkers 
(transforming growth factor-β1 -TGF-β1- and forkhead box protein P3 -FOXP3) together 
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with high expression of T-bet (Th1) and GATA-3 (Th2) demonstrate the deficiency of Treg 
control in CRSwNP patients [31].  
In terms of molecular markers, among Caucasians, IL-5 is the most important cytokine 
found in CRSwNP. IL-5 is related to eosinophil infiltration and activation, and is 
significantly related to recurrence of nasal polyps after surgical removal [32]. Activated 
eosinophils also release several inflammatory mediators, such as leukotrienes, and other 
toxic products (Eosinophil Cationic Protein – ECP, Major Basic Protein – MBP, neurotoxin 
eosinophil protein). Besides the damage induced by infiltrated inflammatory cells, resident 
fibroblasts also play a role in the structural modification of the stroma. Stimulated by 
fibroblast growth factor (FGF) and TGF-β, fibroblasts are recruited, proliferate, and express 
matrix metalloproteinases (MMP), which degrade extracellular proteins (collagen, laminin, 
fibronectin, elastin) and favor tissue edema and albumin deposition. Other cells such as 
eosinophils and neutrophils are also able to produce MMP and may play a role in tissue 
remodeling [33]. Furthermore, fibroblasts suppress the expression of tissue inhibitors of 
metalloproteinases (TIMP) which increase the activity of MMP. Taken together, these 
features explain the main histopathological and molecular findings in CRSwNP, i.e., 
eosinophilic infiltration, tissue edema, and Th2 skewing polarization. 
On the other hand, CRSsNP present some different features compared to CRSwNP. 
Although mixed inflammatory cells are found in CRSsNP, neutrophils are the predominant 
cells in this subset of CRS and,  together with Th1 cells. seem to play the main cellular role in 
the pathogenesis of the disease. Neutrophil markers of activation such as myeloperoxidase 
and IL-8 are found in high levels in CRSsNP compared to controls and CRSwNP. Besides, 
the levels of Th1 cytokines (INF-γ, IL-8) found in CRSsNP are unbalanced with Th2 
cytokines, revealing Th1 polarization. In contrast to CRSwNP, FOXP3 and TGF-β are not 
decreased in CRSsNP, demonstrating that Treg function is not altered in CRSsNP [31]. The 
up-regulated TGF- β signaling pathways are believed to be an important marker that reflects 
the fibrosis/albumin deposition remarkably seen in CRSsNP. (Figure 3) 
In conclusion, in contrast to CRSwNP, the cellular and molecular findings in CRSsNP are 
characterized by neutrophilic infiltration, tissue fibrosis, and Th1 skewing polarization. 
3. Glucocorticoid action on nasal mucosa 
Glucocorticoid (GC) has a broad anti-inflammatory effect, regulating both innate and 
adaptive immune responses in a wide variety of cells, such as epithelial cells, fibroblasts, 
eosinophils and T cells [1, 12, 34]. This is the main reason why GC is considered to be the 
medication of choice to treat chronic rhinitis [2] and rhinosinusitis [8].  
This wide anti-inflammatory effect of GC is explained by several events induced by it, from 
the signaling event to post-translational mechanisms. Basically, GC is a lipophilic compound 
which diffuses though the membrane and binds to its cytoplasmic receptor, called 
glucocorticoid receptor  (GR) [35]. 
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Figure legend: Treg: regulatory T cell; IL: interleukin; INF: interferon; TNF: tumor necrosis factor; Th: T helper cell; 
TGF: transforming growth factor; TIMP: tissue inhibitor of metalloproteinase; MMP: metalloproteinase 
Figure 3. Cellular and molecular events involved in the pathogenesis of CRSsNP. 
GR belongs to a large superfamily of steroid receptors. When inactivated, this receptor stays 
in the cytosol bound to heat shock proteins (hsp) [36]. When GC binds to GR, 
phosphorylation occurs to this receptor, which dissociates GR from hsp. The dimer GC-GR 
is able to translocate into the nucleus and then act as a transcription factor. In this respect, 
the GC-GR dimer can bind directly to a specific palindromic DNA consensus sequence, 
called glucocorticoid response elements (GREs), and consequently induces or inhibits (in 
case of nGREs) the transcription of several genes [35]. Nevertheless, it is recognized that the 
main anti-inflammatory action of GC at the transcriptional level is mediated by a direct 
interaction of GC-GR with other transcription factors (TF), inhibiting their action. This 
inhibition, called “DNA-independent transrepression” affects several pro-inflammatory TF, 
the most important ones being activator protein-1 (AP-1) and nuclear fator-κB (NF-κB) [1, 
35-39] (Figure 4). This connection inhibits gene transcription by direct binding to DNA or by 
inducing histone deacetylation. Although the non-genomic effect of GC is widely known in 
the literature [2, 17], there is no report on its effect on chronic upper respiratory diseases, 
and only few studies have reported controversial results regarding asthma [40, 41]. 
The final effect of GC on nasal diseases is the inhibition of pro-inflammatory cytokines (IL-
1β, TNF-α, GM-CSF, IL-3, IL-5, IL-6), chemokines (IL-8, RANTES, eotaxin) and adhesion 
molecules (VCAM-1, ICAM-1) [1, 13, 42]. Glucocorticoids also have a favorable effect on 
tissue remodeling (reducing MMP expression) [43, 44], reduce mucin production [45], 
increase cell apoptosis [46, 47], and decrease mast cell recruitment and activation [48]. 
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Finally, glucocorticoids inhibit the expression of some cytokine receptors, among them IL-2 
and IL-4 receptors. 
Due to its holistic action, GC is considered to be the best medication for the treatment of 
chronic inflammatory diseases of the upper respiratory airways. 
 
Figure 4. GC mode of action: binding to its cytoplasmic GR, and then translocating into the nucleus. 
GC: glucocorticoid; GR: glucocorticoid receptor; hsp: heat shock protein; GRE: glucocorticoid response 
element; NF-κB: nuclear factor κB; AP-1: activator protein-1 
4. GR splicing 
The GR gene is located in chromosome 5 and is composed of 9 exons. Alternative splicing in 
the ninth exon (hormone-binding domain) gives raise to several alternative GRs, GRα and 
GRβ being the most common [35-39]. 
GRα is the predominant GR isoform. It is transcriptionally active and, when ligated to GC, it 
can translocate into the nucleus, induce expression by binding to GRE, or repress expression 
by either binding to nGRE or by interacting with AP-1 and NF-κB [1, 35, 36]. 
For instance, GRβ is expressed at much lower rates than GRα. It cannot bind to GC, and 
although it can bind to GRE, nGRE, AP-1 and NF-κB, it does not activate their 
transcriptional action. Some authors have shown that, when overexpressed, GRβ inhibits the 
effect of GRα on both transactivation and on AP-1 and NF-κB repression [49-51]. GRβ is 
thus considered to be the dominant negative of GRα; instead, a recent study has shown that 
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a glucocorticoid antagonist, named RU-486, has the ability to bind to GRβ, regulating gene 
expression even in the absence of GRα [52]. 
There is no previous study regarding the influence of GRγ on nasal mucosa. 
5. Resistance to GC 
Although GC is the medication of choice in chronic upper respiratory diseases in general, 
the rate of CG therapy failure in CRSwNP is reported to be between 60 and 80% [8]. 
Although there is no report on GC resistance in chronic rhinitis, resistance is believed to be 
identical to that occurring in CRSwNP. The main reasons for GC failure are: limited action 
of topical GC in extensive diseases [53], poor compliance with treatment [54] , and 
cellular/molecular resistance to GC [36, 55]. Among cellular and molecular mechanisms of 
GC resistance, the main lines investigated are GRα- GRβ interaction and TF influence. 
One of the most studied mechanisms is the GRα-GRβ imbalance. Although GRβ is able to 
interact directly with GRα within the nucleus, it has a low capacity to bind to GC. This is 
why GRβ is considered to be an endogenous inhibitor of GRα [36, 56]. GRα-GRβ imbalance 
has been reported to increase cell resistance in chronic immune-mediated diseases, among 
those affecting the upper [37, 57] and lower airways [58, 59]. 
Increased expression of GRβ has been widely reported in the literature on inflammatory 
respiratory diseases such as CRSwNP and asthma, when compared to control mucosa [36, 
55, 60, 61]. This has led to the hypothesis that increased GRβ expression could impair the 
action of GC. Decreased expression of GRα has also been recently reported in CRswNP with 
the use of a more reliable quantitative method of analysis [56, 62, 63]. More important than 
the expression of each individual isoform, GRα-GRβ imbalance might be the most relevant 
determinant of GC resistance. It is important to mention that some studies have 
demonstrated that CG therapy in CRSwNP does not change GR isoform expression or the 
GRα-GRβ relation [56, 63, 64]. 
Higher expression of TF could also lead to GC resistance, because TF (mainly AP-1 and NF-
κB) repress the binding of the translocated GC-GR complex to GRE. This mechanism of GC 
resistance has been reported in several inflammatory diseases, such as inflammatory bowel 
diseases. Nevertheless, this mechanism has been poorly reported in respiratory diseases. 
AP-1 is a dimer predominantly consisting of c-Fos/c-Jun heterodimers. As is the case for 
most TF, they are located in the cytoplasm and, when activated, translocate into the nucleus 
and induce the expression of several pro-inflammatory genes which regulate cell 
inflammation, proliferation, differentiation and apoptosis [65]. Conflicting results have been 
reported regarding the presence of AP-1 in CRSwNP. c-Fos expression has been studied in 
two reports because it is more important regarding the transcriptional action. One study [66] 
has reported an increased presence of c-Fos in patients with CRSwNP than in control 
mucosa using qualitative PCR, while the other [56] has observed a similar expression in the 
two groups using quantitative RT-PCR. The latter study also did not observe any influence 
of c-Fos expression on the outcome of GC treatment. 
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NF-κB is also a heterodimer, mainly consisting of p50 and p65 isoforms. When activated, 
NF-κB translocates into the nucleus, and p65 directly binds to DNA, inducing gene 
expression of pro-inflammatory and anti-apoptotic genes [37, 65]. NF-κB is considered 
pivotal to the regulation of immune and inflammatory genes, and its absence is 
incompatible with life. It is important to mention that the most important pro-inflammatory 
cytokines (IL-1β and TNF-α), whose expression is considerably influenced by NF-κB, also 
activate NF-κB translocation, inducing perpetuation of the inflammatory process. 
Two studies have reported increased expression of both isoforms (p50 and p65) of NF-κB in 
patients with CRSwNP when compared to control nasal mucosa [56, 67]. Also, a high 
expression of p65 was related to a poor clinical outcome in response to medical treatment in 
CRSwNP patients [56]. This finding suggests that NF-κB may also have a pivotal effect on 
GC resistance. 
6. Conclusions 
Chronic inflammatory nasal diseases are highly prevalent in the population, and therefore 
nasal TGC has been widely prescribed by physicians. Considering that a high percentage of 
these patients only partially benefit from TGC, or do not respond to TCG treatment at all, 
the understanding of possible mechanisms of GC resistance is essential for future 
treatments. 
Today, it has been accepted that cellular and molecular mechanisms of resistance do exist 
in nasal mucosa. Future investigations are still required to recognize affected individuals 
and how this would influence medical treatment. This will be essential to develop new 
drugs that would replace or act synergistically with CG, in order to improve the clinical 
outcome. 
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